Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: A systematic review

Lung

Volumn 191, Issue 2, 2013, Pages 135-146

  Jiang, Fa Ming ^a   Liang, Zong An ^a   Zheng, Qiao Ling ^a   Wang, Rong Chun ^a   Luo, Jian ^a   Li, Chun Tao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

COPD; Efficacy; Indacaterol; Meta analysis; Safety; Systematic review

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; INDACATEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COCHRANE LIBRARY; DATA EXTRACTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EMBASE; ENGLISH AS A SECOND LANGUAGE; FORCED EXPIRATORY VOLUME; HEART ARREST; HUMAN; INFORMATION PROCESSING; MEDLINE; META ANALYSIS; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; LUNG; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84880572821     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9444-2     Document Type: Review

References (30)

1. World Health Organisation (WHO) World Health Statistics. Available at: http://www.who.int/whosis/whostat/EN WHS08 Full.pdf
2. Global initiative for chronic obstructive lung disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2011. Available at: www.goldcopd.com
3. Food and Drug Administration (FDA) FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm261649.htm
4. Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T (2010) Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD 7:418-427. doi: 10.3109/15412555.2010.528812
5. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M et al (2010) Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 11:135-142. http://respiratory-research.com/content/11/1/135
6. LaForce C, Aumann J, Parreño L, Iqbal A, Young D, Owen R et al (2011) Sustained 24-hour efficacy of once daily indacaterol (300 mg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther 24:162-168
7. O'Donnell DE, Casaburi B, Vincken W, Puente-Maestu L, Swales J, Lawrence D et al (2011) Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 105:1030-1036. doi: 10.1016/j.rmed.2011.03. 014
8. Magnussen H, Verkindre C, Jack D, Jadayel D, Henley M, Woessner R et al (2010) Indacaterol once a day is equally effective dosed in the evening or morning in COPD. Respir Med 104:1869-1876. doi: 10.1016/j.rmed.2010.08.010
9. van Noord JA, Buhl R, LaForce C, Martin C, Jones F, Dolker M et al (2010) QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65:1086-1091. doi: 10.1136/thx.2010.139113
10. Beier J, Chanez P, Martinot J-B, Schreurs AJ, Tkacova R, Bao W et al (2007) Safety, tolerability and efficacy of indacaterol, a novel once a day b2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 20:740-749. doi: 10.1016/j.pupt.2006.09.001
11. Beeh K-M, Wagner F, Khindri S, Drollmann AF (2011) Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 8:340-345. doi: 10.3109/15412555.2011.594464
12. Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M et al (2010) Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 23:165-171. doi: 10.1016/j.pupt.2010.01.003
13. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, Chuchalin A et al (2008) A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 102:1033-1044. doi: 10.1016/j.rmed.2008.02. 001
14. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C et al (2011) Indacaterol once a day provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 105:719-726. doi: 10.1016/j.rmed.2011.02.008
15. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R et al (2010) Efficacy and safety of indacaterol 150 microg once a day in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 10:11-19. http://dx.doi.org/10.1186/1471-2466-10-11
16. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorganciog ̌lu A et al (2010) Once a day bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182(2):155-162. http://dx.doi.org/10.1164/rccm.200910-1500OC
17. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D et al (2010) Efficacy of a new once a day long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65(6):473-479. http://dx.doi.org/10.1136/thx.2009.125435
18. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C et al (2011) Once a day indacaterol vs. twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37:273-279 http://dx.doi.org/10.1183/09031936.00045810
19. Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M et al (2011) Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med 106(1):84-90. doi: 10.1016/j.rmed.2011. 09.006
20. Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B et al (2010) Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulm Dis 5:311-318
21. Beier J, Beeh K-M, Brookman L, Peachey G, Hmissi A, Pascoe S (2009) Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 22:492-496. doi: 10.1016/j.pupt.2009.05.001
22. Kato M, Makita H, Uemura K, Fukuchi Y, Hosoe M, Emery C et al (2010) Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: a randomised, double-blind, placebo-controlled trial. Allergol Int 59:285-293. doi: 10.2332/allergolint.10-OA-0173
23. Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R et al (2009) 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 25(2):463-470. doi: 10.1185/03007990802675096
24. Mahler DA, Witek TJ Jr (2005) The MCID of the transition dyspnea index is a total score of one unit. COPD 2:99-103
25. Witek TJ Jr, Mahler DA (2003) Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 21:267-272
26. Partridge MR, Miravitlles M, Ståhl E, Karlsson N, Svensson K, Welte T (2010) Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J 36(1):96-104. http://dx.doi.org/10.1183/09031936.00123709
27. Jones PW, Quirk FH, Baveystock CM, Littlejohns P (1992) A self-complete measure for chronic airflow limitation: the St George's respiratory questionnaire. Am Rev Respir Dis 55(6):1321-1327
28. Jones PW (2005) St George's respiratory questionnaire: MCID. COPD 2:75-83
29. Jones PW, Mahler DA, Gale R, Owen R, Kramer B (2011) Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med 105(6):892-899
30. Jones PW, Barnes N, Vogelmeier C, Lawrence D, Kramer B (2011) Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J 20(4):380-388